Industry Partners

Partnering with BioCurate provides a unique opportunity for industry and the wider sector to keep up to date with the latest, most promising discoveries from two of Australia’s leading Universities in biomedical research and affiliated medical research institutes. BioCurate is dedicated to working with all stakeholders in a collaborative and professional manner that will foster productive and long-term relationships.


BioCurate aims to draw upon the expertise of industry and the sector to help guide and progress projects, to educate and develop researchers, and to facilitate new collaborations. For industry, there are several opportunities in which to become involved, whether it be during or after each step of BioCurate’s formal review process. The focus at each stage of review is summarised as follows:

  • Initial screening – Review of a large number of potential projects including detailed discussions with researchers to assist them with project planning and building their understanding.
  • Tier 1 Review – Unmet need, potential regulatory and clinical development path
  • Tier 2 Review – New therapeutic development
  • Tier 3 Review(s) – Plan for IND, evaluate data with select appropriate international industry experts


BioCurate aims to complement, rather than compete with, the Venture Capital and biopharma-industry investment sectors by improving the quality and quantity of ‘investment-ready’ assets in the new drug project pipeline that are available for investment and partnering. Critical to this success will be BioCurate’s reputation and credibility as an attractive partner that understands the requirements of investors and industry.

BioCurate’s industry engagement strategy was developed and commenced implementation in 2018 with a number of very encouraging early achievements. To date, BioCurate has announced several formal industry collaborations, and the co-investment and formation of a spin-out company to develop University IP.


Currently, BioCurate has signed a Memorandum of Understanding with the following biopharmaceutical companies:

Return to Collaborators